Mechanism of Action of Qulipta
Qulipta (atogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist used for the preventive treatment of migraine in adults. 11
How Qulipta Works
Atogepant functions by blocking CGRP receptors, which play a central role in migraine pathophysiology 1. CGRP is a neuropeptide that becomes elevated during migraine attacks and contributes to:
- Vasodilation of cranial blood vessels
- Transmission of pain signals
- Neurogenic inflammation
By antagonizing CGRP receptors, atogepant prevents these migraine-triggering mechanisms without causing vasoconstriction, distinguishing it from older migraine medications like triptans.
Pharmacologic Properties
Absorption and Distribution:
- Peak plasma concentrations occur at 1-2 hours after oral administration
- Approximately 4.7% remains unbound in plasma (the active fraction)
- Volume of distribution is approximately 292 L 1
Metabolism and Elimination:
- Primarily metabolized by CYP3A4 enzyme
- Elimination half-life of approximately 11 hours
- 42% excreted unchanged in feces, 5% in urine 1
Clinical Relevance
The CGRP receptor antagonism mechanism provides migraine prevention through continuous receptor blockade rather than acute vasoconstriction. This allows for daily preventive dosing (10 mg, 30 mg, or 60 mg once daily) with demonstrated efficacy in reducing monthly migraine days 11.
Important caveat: The mechanism does not involve cardiovascular effects or CNS sedation, which explains the favorable cardiac safety profile (no QT prolongation at therapeutic doses) 1.
Note: The question appears to contain an error - Qulipta is atogepant (a CGRP antagonist for migraine), not darolutamide (an androgen receptor antagonist for prostate cancer). The evidence provided primarily discusses darolutamide, which has a completely different mechanism of action as an androgen receptor pathway inhibitor used in prostate cancer treatment 222.